

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

NEW LINCOLNSHIRE GUIDANCE ON THE MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Summary of PACEF decisions from October 2015

For further details see *PACE Bulletin* Volume 9 No 17 (October 2015)

Drug	Indication(s)	Traffic Light and Joint Formulary Status
Ciclesonide 80 microgram and 160 microgram per actuation metered dose inhaler (Alvesco) (Takeda)	For persistent asthma.	AMBER for use following specialist recommendation only. Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see Step 3(a) of the chronic asthma in adults guidance
Long acting beta agonist (LABA) Indacaterol 150 microgram and 300 microgram capsule plus inhaler (Onbrez Breezhaler) Novartis)	For the maintenance treatment of COPD.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Long acting beta agonist (LABA) Olodaterol 2.5microgram per dose 60 dose cartridge plus Respimat device (Striverdi Respimat) (Boehringer Ingelheim)	A long acting once daily bronchodilator for the maintenance treatment of patients with chronic obstructive pulmonary disease.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Long-Acting Muscarinic Antagonist (LAMA) Aclidinium bromide 322 microgram per dose dry powder inhaler (Eklira Genuair) (AstraZeneca)	For the maintenance treatment of COPD.	GREEN. Included in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.
Long-Acting Muscarinic Antagonist (LAMA) Glycopyrronium bromide 50 microgram capsule plus inhaler (Seebri Breezhaler) (Novartis)	For the maintenance treatment of COPD.	GREEN. Included in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.
Long-Acting Muscarinic Antagonist (LAMA) Tiotropium 18microgram capsule plus Handihaler (Spiriva) (Boehringer Ingelheim)	For the maintenance treatment of COPD.	GREEN. Included in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.
Long-Acting Muscarinic Antagonist (LAMA) Tiotropium 2.5microgram cartridge plus Respimat device (Spiriva Respimat) (Boehringer Ingelheim Ltd)	For the maintenance treatment of COPD. For use as add-on maintenance treatment of asthma in patients receiving inhaled corticosteroids and LABAs with more than one severe exacerbation in the previous year.	GREEN. Included in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance and Step 4 of the chronic asthma in adults guidance
Long-Acting Muscarinic Antagonist (LAMA) Umeclidinium dry powder inhaler (Incruse Ellipta) (GlaxoSmith Kline)	For the maintenance treatment of COPD.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.

<p>LABA/Inhaled corticosteroid (ICS) combination products Budesonide/ formoterol fumarate dehydrate breath actuated dry powder inhaler 160/4.5 and 320/9 (DuoResp Spiromax) (Teva)</p>	<p>Inhaled corticosteroid/long acting bronchodilator combination dry powder inhaler for the regular treatment of asthma and the symptomatic treatment of severe COPD with a history of repeated exacerbations despite regular therapy with long-acting bronchodilators.</p>	<p>GREEN. Approved for inclusion in the Lincolnshire Joint Formulary. Alternative to Symbicort Turbohaler at equivalent dose. For place in therapy see Step 3 of guidance on the management of chronic asthma in adults and guidance on the management of COPD.</p>
<p>LABA/Inhaled corticosteroid (ICS) combination products Formoterol/beclometasone metered dose inhaler 6 microgram/ 100microgram per dose (Fostair) (Chiesi)</p>	<p>For the regular treatment of asthma where LABA/ICS combination therapy is appropriate. For the symptomatic treatment of severe COPD with a post-bronchodilator FEV1 <50% predicted and a history of exacerbations despite regular bronchodilator therapy</p>	<p>GREEN. Included in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance and Step 3(a) of the chronic asthma in adults guidance.</p>
<p>LABA/Inhaled corticosteroid (ICS) combination products Formoterol/ beclometasone dry powder inhaler (Fostair NEXThaler) (Chiesi)</p>	<p>For the regular treatment of asthma in adults where LABA/ICS therapy is appropriate</p>	<p>GREEN Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see Step 3 of guidance on the management of chronic asthma in adults.</p>
<p>LABA/Inhaled corticosteroid (ICS) combination products Salmeterol xinafoate 25 microgram/ fluticasone propionate 125 or 250 microgram inhaler (Sirdupla) (Mylan)</p>	<p>For the regular treatment of asthma where long acting β2-agonist and inhaled corticosteroid is appropriate.</p>	<p>GREEN Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see Step 3 of guidance on the management of chronic asthma in adults. New low cost equivalent to Seretide Evohaler.</p>
<p>LABA/Inhaled corticosteroid (ICS) combination products Vilanterol/ fluticasone furoate combination inhaler (Relvar Ellipta) (GlaxoSmithKline)</p>	<p>A combination LABA/ICS inhaler for the regular treatment of asthma and symptomatic treatment of chronic obstructive pulmonary disease with a post-bronchodilator FEV1 <70% predicted and a history of exacerbations despite regular bronchodilator therapy.</p>	<p>RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.</p>
<p>LABA/Long Acting Muscarinic Antagonist (LAMA) combination products Formoterol fumarate dihydrate/ aclidinium bromide dry powder inhaler (Duaklir Genuair) (AstraZeneca)</p>	<p>For the maintenance treatment of COPD</p>	<p>GREEN Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.</p>
<p>LABA/Long Acting Muscarinic Antagonist (LAMA) combination products Indacaterol/ glycopyrronium bromide breath activated dry powder inhaler (Ultibro Breezhaler) (Novartis)</p>	<p>For the maintenance treatment of COPD</p>	<p>GREEN Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.</p>
<p>LABA/Long Acting Muscarinic Antagonist (LAMA) combination products Olodaterol/ tiotropium bromide monohydrate) inhaler (Spiolto Respimat) (Boehringer Ingelheim Ltd)</p>	<p>For the maintenance treatment for COPD</p>	<p>GREEN Approved for inclusion in the Lincolnshire Joint Formulary. For place in therapy see COPD guidance.</p>
<p>LABA/Long Acting Muscarinic Antagonist (LAMA) combination products Vilanterol/ umeclidinium dry powder inhaler (Anoro Ellipta) (GlaxoSmithKline)</p>	<p>For the maintenance treatment of COPD</p>	<p>RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.</p>

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION